美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · RCKT近 30 天 7 則 · 第 1 / 1 頁
- Ultragenyx 將 Sanfilippo 基因療法定價為 400 萬美元；Bristol Myers 擱置 Orum 藥物Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
- RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
- Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls
- Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
- Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
- Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
- Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
- Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
- Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says
- Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
- Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
- Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
- Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。